Caveolin-1 and breast cancer: A new clinical perspective

Advances in Experimental Medicine and Biology

Volumn 729, Issue , 2012, Pages 83-94

  Mercier, Isabelle ^a   Lisanti, Michael P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; TAMOXIFEN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CAVEOLIN 1 GENE; CELL PROLIFERATION; DRUG EFFECT; ENERGY TRANSFER; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; INTRACELLULAR SIGNALING; KNOCKOUT MOUSE; MITOCHONDRIAL RESPIRATION; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STROMA CELL; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST NEOPLASMS; CAVEOLIN 1; CELL PROLIFERATION; ESTROGENS; HUMANS; MUTATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84859805425     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-1222-9_6     Document Type: Article

References (48)

1. Oka N, Yamarnoto M, Schwencke C et al. Caveolin interaction with protein kinase C: Tsoenzyme-dependent regulation of kinase activity by the caveolin-scaffolding domain peptide. J Biol Chem 1997; 272 :334 16-3342 1.
2. Couet J, Li S, Okamoto T et al. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem 1997; 272:6525-6533.
3. OkamotoT, SchlegelA, Scherer PE et al. Caveolins,Afamily of scaffoldingproteins fo rorganizing"pre-assembled signaling complexes" at the plasma membrane. J Biol Chem (Mhi-review) 1998; 273:5419-5422.
4. EngelmanJA,ZhangXL,Galbiati F et al. Molecular Genetics of the Caveolin Gene Family: Implications for Human Cancers, Diabetes, Alzheimer' s Disease, and Muscular Dystrophy. Am J Hum Genetics 1998; 63:1578-1587.
5. Smart EJ, Graf GA, McNiven MA et al. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 1999; 19:7289-7304.
6. Koleske AJ, Baltimore D, Lisanti MP. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 1995; 92:1381-1385.
7. Engelman JA, Wykoff CC, Yasuhara S et al. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem 1997; 272:16374-16381.
8. Galbiati F, Volonte D, Engelman JA et al. Targeted downregulation of caveolin-1 is sufucient to drive cell transformation and hyperactivate the p42 44 MAP kinase cascade. EMBO J 1998; 17:6633-6648.
9. EngelmanJA, ZhangXL, Galbiati F et al. Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cay-1, -2 and -3). Cay-i and Cav-2 genes map to a known tumor suppressor locus (6-A2 7q31). FEBS Left 1998; 429:330-336.
10. Sotgia F, Williams TM, Schubert Wet al. Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am J Pathol 2006; 168:292-309.
11. Fiucci G, Ravid D, Reich Ret al. Caveolin-1 inhibits anchorage- independent growth, anoikis andinvasiveness in MCF-7 human breast cancer cells. Oncogene 2002; 21:2365-2375.
12. Zhang X, Shen P, Coleman M et al. Caveolin-1 down-regulation activates estrogen receptor alpha expression and leads to l7beta-estradiol-stimulated mammary tumorigenesis. Anticancer Res 2005; 25:369-375.
13. Zhang W, Razani B, Altschuler Yet al. Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressoreffects ofadenovirus-mediatedgenedeliveryof caveolin-1. J Biol Chem 2000; 275:20717-20725.
14. Lee SW, Reimer CL, Oh P et al. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 1998; 16:1391-1397.
15. Wu P, Wang X, Li F et al. Growth suppression of MCF-7 cancer cell-derived xenografls in nude mice by caveolin-1. Biochem Biophys Res Commun 2008; 376:215-220.
16. Lee H, Park DS, Razani B et al. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: Caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol 2002; 161:1357-1369.
17. Williams TM, Medina F, Badano I et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo: Role of Cay-i in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 2004; 279:51630-51646.
18. Bonuccelli G, Casimiro MC, Sotgia F et al. Caveolin-1 (P1 32L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell metastasis-associated gene signature. Am J Pathol 2009; 174:1650-1662.
19. Hayashi K, Matsuda S, Machida K et al. Invasion activating caveolin-1 mutation in human scinhous breast cancers. Cancer Res 2001; 61:2361-2364.
20. Mercier I, Bryant KG, Sotgia F et al. Using Caveolin-1 epithelial immunostaining patterns to stratifS human breast cancer patients and predict the Caveolin-1 (P 132L) mutation. Cell Cycle 2009; 8(9): 1396-401.
21. Li T, Sotgia F, Vuolo MA et al. Caveolin-1 mutations in human breast cancer: Functional association with estrogen receptor alpha-positive status. Am J Pathol 2006; 168:1998-2013.
22. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001; 344:276-285.
23. Lacroix M, Toillon RA, Leclercq G. Stable 'portrait' of breasttumors during progression: Data from biology, pathology and genetics. Endocr Relat Cancer 2004; 11:497-522.
24. Foster JS, Henley DC, Ahamed S et al. Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metab 2001; 12:320-327.
25. Mercier I, Casimiro MC, Zhou Jet al. Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. Am J Pathol 2009; 174:1172-1190.
26. Zou W, McDaneld L, Smith LM. Caveolin-1 haploinsufuciency leads to partial transformation of human breast epithelial cells. Anticancer Res 2003; 23:4581-4586.
27. Olewniczak S, Chosia M, Kwas Aet al. Angiogenesis and some prognostic parameters of invasive ductal breast carcinoma in women. Pol J Pathol 2002; 53:183-188.
28. Jung DJ, Na SY, Na DS et al. Molecular cloning and characterization of CAPER, a novel coactivator of activating protein-i and estrogen receptors. J Biol Chem 2002; 277:1229-1234.
29. Itahana K, Bhat KP, Jin A et al. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 2003; 12:1151-1164.
30. OrimoA, Gupta PB, Sgroi DC et al. Stromalfibroblasts present in invasive humanbreast carcinomas promote tumor growth and angiogenesis through elevated SDF-1 CXCL12 secretion. Cell 2005; 121:335-348.
31. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle 2006; 5:1597-1601.
32. Shimoda M, Mellody KT, Orimo A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dcv Biol 2010; 21(1):19-25.
33. Ostman A, Augsten M. Cancer-associated tibroblasts and tumor growth-bystanders turning into key players. Cun Opin Genet Dcv 2009; 19:67-73.
34. RyanGB, CliffWJ, Gabbiani G et al. Myofibroblasts in human granulation tissue. Hum Pathol 1974; 5:55-67.
35. Oliver N, Babu M, Diegelmann R. Fibronectin gene transcription is enhanced in abnormal wound healing. J Invest Dermatol 1992; 99:579-586.
36. Babu M, Diegelmann R, Oliver N. Fibronectin is overproduced by keloid fibroblasts during abnormal wound healing. Mol Cell Biol 1989; 9:1642-1650.
37. Pavlides S, Tsirigos A, Migneco Get al. The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in theling tumor cell metabolism. Cell Cycle 2010; 9(20:4297-306.
38. Martinez-Outschoorn UE, Balliet RM, Rivadeneira et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 1010; 9(16):3256-76.
39. Mercier I, Casimiro MC, Wang C et al. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulationand RB tumor suppressor functional inactivation: Implications for theresponse tohormonal therapy. Cancer Biol Ther 2008; 7:1212-1225.
40. Witkiewicz AK, Dasgupta A, Sotgia F et al. An absence of stromal caveolin-1 expression predicts early tumor recunence and poor clinical outcome in human breast cancers. Am J Pathol 2009; 174:2023-2034.
41. Witkiewicz AK, Dasgupta A, Sammons S et al. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther 2010; 10(2):135-43
42. Witkiewicz AK, Dasgupta A, Nguyen KH et al. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther 2009; 8:1071-1079.
43. KunduM,ThompsonCB.Autophagy: Basic principles and relevance to disease.Annu Rev Pathol 2008; 3:427-455.
44. Yang Z, Klionsky DJ. An overview of the molecular mechanism of autophagy. Cun Top Microbiol Immunol 2009; 335:1-32.
45. HeC,KlionskyDJ. Regulation mechanisms and signaling path ways of autophagy.Aimu Rev Genet 2009;43:67-93.
46. Di Vizio D, Morello M, Sotgia F et al. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle 2009; 8:2420-2424.
47. Martinez-Outschoorn UE, Trimmer C, Lin Z et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. Cell Cycle 2010; 9(17):35 15-3533.
48. Marthez-OutschoomUE,Whitaker-Menezes D, Pavlides S etal. The autophagic tumor stroma model of cancer or "battery-operated tumor growth":A simple solutionto the autophagyparadox. Cell Cycle 2010; 9(20:4297-306